JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Rat
Purified Recombinant Mouse RANKL (NSO-derived)
≥ 5.0 mg/ml
≥95% monomer by analytical SEC
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Next Day 2-8°C
FC The suggested concentration for RANKL antibody, clone IK22/5 for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl or 100 μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. WB The suggested concentration for this RANKL antibody for use in western blotting is 1-10 μg/ml.
BIP
Clone IK22/5 recognizes an epitope on mouse RANKL.
RANKL is expressed on activated T cells and osteoclasts.
RANKL antibody, clone IK22/5, recognizes receptor activator of NF-κB ligand (RANKL), also known as CD254, TNF-related activation-induced cytokine (TRANCE), tumor necrosis factor ligand superfamily member 11 (TNFSF11), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF). RANKL is a type II transmembrane protein belonging to the TNF cytokine superfamily and binds to the signaling receptor, RANK, or decoy receptor, osteoprotegerin (OPG). RANKL is expressed on osteoclasts and is essential for osteoclast differentiation, activation, and survival1. RANKL is also expressed on activated T cells and regulates T cell-dendritic cell (DC) interactions, enhancing DC activation and survival2-3. In addition, RANKL is crucial for lymph node, bone marrow, and thymus development4. Treatment with denosumab, an antibody directed against RANKL, is approved for the treatment of patients at high risk for bone fractures, including osteoporosis, and has shown anti-tumor effects5.
RANKL
RANK, OPG
21943
Information on Uniprot.org
1. Park JH, et al. (2017) Mol Cells. 40(10):706-7132. Wong BR, et al. (1997) J Biol Chem. 272(40):25190-43. Anderson, D. M., et al. (1997) Nature 390:175.4. Ono T, et al. (2020) Inflamm Regen. 2020; 40:2. 5. de Groot AF, at al. (2018) Cancer Treat Rev. 62:18-28
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Delivery expected until 8/28/2025
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!